The ‘New to Partnership Payment Scheme’ (N2PP) is a new commitment from the Update to the GP Contract agreement 2020/21–2023/24, forming part of the suite of interlocking GP recruitment and retention initiatives
The overarching aim of the ‘New to Partnership Payment Scheme’ (N2PP) is to grow the number of partners – and individuals with equivalent status – working in primary care, stabilising the partnership model and helping to increase clinicians’ participation levels so that primary medical care, and the patients it serves, have access to the workforce they need.
The N2PP scheme gives eligible participants a sum of up to £20,000, plus a contribution towards on-costs of up to £4,000 (for a full-time participant), to support their establishment as a partner, as well as up to £3,000 as a training fund to develop non-clinical partnership skills. In order to participate in the scheme applicants will be required to ensure that they submit an application form and supplementary evidence to NHSEI and meet the eligibility criteria. In order to be eligible to participate in the scheme, an applicant must:
be a healthcare professional working in general practice who is registered with their respective professional body and delivering clinical care to patients in general practice through a GMS/PMS/APMS contract;
not have been a partner in a GP practice before;
hold a profit-shares, legally-liable partnership;
commit to remaining a partner in a GP practice for five years (or pay back a portion of the loan)
deliver a minimum of two clinical sessions per week in their partnership practice throughout the five-year period;
have signed a partnership agreement on or after 1 April 2020 and before the scheme closes;
have a minimum of two years remaining in their contract.
Interested colleagues and their practices should review the New to Partnership Payment Scheme guidance, complete the online application and provide supplementary evidence to support their applications. All prospective applicants are encouraged to take their own financial advice before applying to the scheme.
If you experience any issues logging in to, or using, the online portal, guidance is available on the Future NHS Collaboration Portal (this platform requires a log-in) or contact the team on [email protected].
Please refer to the privacy notice for details of how NHS England will use the personal information that you provide.
If you don’t already hold a Future NHS account you can simply register via the Future NHS login page. Should you have any issues accessing the platform please contact the primary care workforce team at [email protected].
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events relating to CSL Seqirus products should also be reported to Seqirus UK Limited on 01748 828816.
1. Seqirus Data on File, August 2023. SREF–17994. 2. Adjuvanted Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics. 3. Cell-based Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics.
Be the first to comment